- Home
- AKAM vs ABVX Comparison
AKAM vs ABVX Comparison
Compare AKAM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKAM | ABVX |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.2B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | AKAM | ABVX |
|---|---|---|
| Price | $92.78 | $118.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $97.43 | ★ $130.09 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 02-19-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.97 | N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | ★ $4,133,202,000.00 | $6,231,374.00 |
| Revenue This Year | $7.09 | $6.80 |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $26.25 | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $67.51 | $4.77 |
| 52 Week High | $103.75 | $148.83 |
Technical Indicators
Market Signals| Indicator | AKAM | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 46.79 |
| Support Level | $89.23 | $113.64 |
| Resistance Level | $95.04 | $122.50 |
| Average True Range (ATR) | 2.71 | 8.73 |
| MACD | 0.37 | -1.49 |
| Stochastic Oscillator | 79.94 | 31.67 |
Price Performance
Historical ComparisonAbout AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.